Hyponatremia from oxcarbazepine and carbamazepine.
The authors examined sodium concentrations from 97 oxcarbazepine-treated (OXC) and 451 carbamazepine-treated (CBZ) patients with epilepsy using cross-section and follow-up studies. The frequency of hyponatremia (Na+ < or = 134 mEq/L) was 29.9% among OXC-treated patients and 13.5% among CBZ-treated patients (p < 0.0001). Hyponatremia (Na+ < or = 128 mEq/L) was severe: 12.4% of OXC-treated patients and 2.8% of CBZ-treated patients (p < 0.001). Advanced age was a risk factor for hyponatremia. Hyponatremia, once present, persisted in both groups.
Dong
Xiaoming
X
Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA. dongx015@umn.edu
Leppik
Ilo E
IE
White
James
J
Rarick
John
J
D000328:Adult; D000367:Age Factors; D000375:Aging / Q000502:physiology; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects; D002220:Carbamazepine / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D016208:Databases, Factual; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions / Q000502:physiology; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology; D000077287:Levetiracetam; D008297:Male; D008875:Middle Aged; D000078330:Oxcarbazepine; D010889:Piracetam / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D015995:Prevalence; D012737:Sex Factors; D012964:Sodium / Q000097:blood
D000927:Anticonvulsants; D002220:Carbamazepine; D000077287:Levetiracetam; D012964:Sodium; D000078330:Oxcarbazepine; D010889:Piracetam